logo

For the Inventor, By the Inventor

Indianapolis, IN, United States of America

Larry W Hertel

This inventor holds 21 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignee: Eli Lilly and Company. Active years: 1985-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Larry W Hertel. Retrieved from https://idiyas.com/inventor/larry-w-hertel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21

% Patents Active = 95.2

Average Co-Inventor Count = 2.0

ph-index = 8

Forward Citations = 474(Granted Patents)


Company Filing History:

goldMedal21 out of 4,514 
 
Eli Lilly and Company
 patents

Years Active: 1985-2007

Loading Chart...
Areas of Expertise:
Melanocortin Receptor Agonists
Azepine Derivatives
Serotonin Systems
Piperidine Derivatives
Pyrrolidine Derivatives
Difluoro Antivirals
Nucleosides
Tumor Treatment
Anomeric Fluororibosyl Amines
Stereoselective Glycosylation
Chemical Intermediates
Photochemical Conversion
21 patents (USPTO):Explore Patents
1. 7291619 - Melanocortin receptor agonists (2007-11-06),
2. 6465453 - Azepine derivatives having effects on serotonin related systems (2002-10-15),
3. 6436964 - Piperidine derivatives having effects on serotonin related systems (2002-08-20),
4. 6353008 - Pyrrolidine and pyrroline derivatives having effects on serotonin related systems (2002-03-05),
5. 5744597 - Stereoselective anion glycosylation process for preparing (1998-04-28),
6. 5644043 - 2',3'-dideoxy-2',2'-difluoronucleosides and intermediates (1997-07-01),
7. 5594155 - Anomeric fluororibosyl amines (1997-01-14),
8. 5574021 - Methods of treatment using 2',3'-dideoxy-2',2'-difluoronucleosides (1996-11-12),
9. 5541345 - Anomeric fluororibosyl amines (1996-07-30),
10. 5480992 - Anomeric fluororibosyl amines (1996-01-02),
11. 5464826 - Method of treating tumors in mammals with 2',2'-difluoronucleosides (1995-11-07),
12. 5430026 - 2'-deoxy-2',2'-difluoro (4-substituted pyrimidine) nucleosides, bicyclic (1995-07-04),
13. 5118820 - Difluro antivirals and intermediate therefor (1992-06-02),
14. 5061793 - 2-deoxy-2',2'-difluoro-inosine and 5'O-derivatives (1991-10-29),
15. 5015743 - Difluoro antivirals and intermediate therefor (1991-05-14),

Title: Innovations by Larry W. Hertel in Pharmaceutical Patents

Introduction

Larry W. Hertel is a renowned inventor based in Indianapolis, IN, with an impressive portfolio of 21 patents. His contributions primarily focus on pharmaceutical innovations that address significant health challenges.

Latest Patents

Among Larry's most recent patents is the development of melanocortin receptor agonists. This invention relates to compounds that are beneficial for the treatment of obesity, diabetes, and sexual dysfunction in both males and females. In addition, he has worked on azepine derivatives that affect serotonin-related systems. This particular invention involves compounds designed to inhibit the reuptake of serotonin and antagonize specific serotonin receptors, showcasing a novel method for treating related disorders.

Career Highlights

Larry has made significant strides in the pharmaceutical field and is currently employed at Eli Lilly and Company, a prominent player in drug development and biotechnology. His work has paved the way for innovative therapies that address critical health conditions.

Collaborations

Throughout his career, Larry has collaborated with esteemed colleagues such as Julian Stanley Kroin and Charles David Jones. These partnerships have fostered an environment for creative problem-solving and have led to groundbreaking advancements in the pharmaceutical industry.

Conclusion

Larry W. Hertel's patents reflect his commitment to improving healthcare through innovative solutions. His work continues to inspire future advancements in the treatment of various medical conditions, reinforcing the importance of research and development in the pharmaceutical realm.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…